Our results demonstrated that the status of genomic alterations of several oncogenic driver genes, such as EGFR, ALK, and ROS1, as well as several frequently mutated genes in NSCLC (e.g., TP53), correlated with the expression of PD‐L1 and TMB. This evidence concerns the gene TP53 and non-small cell lung carcinoma.